Abcam

Quality Assistance S.A. is a leading European Contract Research Organisation providing the pharmaceutical industry with all the analytical services required by EMA and FDA regulations for the development and marketing of innovative human medicinal products.

We assist our clients from candidate selection, through non-clinical and clinical studies, to marketing authorisation, using our state-of-the-art, product-dedicated expertise in analytical sciences.

For each customer and each project, we design customised solutions, define analytical protocols, develop and validate specific new analytical methods and perform characterisation, stability, pharmacokinetic, biomarker and immunogenicity studies as well as batch release testing, in order to evaluate the Quality, Safety and Efficacy of the given drugs.

Quality Assistance S.A. is an expert for the development of:
- Biologics (monoclonal antibodies, ADCs, proteins)
- New Chemical Entities, oligonucleotides, peptides
- Nanomedicine products
- Vaccines
- Cell-Based and Gene Therapy Medicinal Products

The company holds a unique position on the market with:
All its laboratories on one site (Donstiennes, Belgium)
- Bioanalysis (PK/TK/Immuno)
- Bioassays
- Biochemistry
- Chromatography
- Elemental Impurities
- Mass Spectrometry
- Microbiology
- Molecular Biology
- Protein Characterisation
200 highly qualified professionals
more than 35 years’ expertise at the forefront of analytical sciences.

Our core competencies are:
QUALITY (CMC)
- Development and validation of analytical methods
- Characterisation
- Stability studies
- Batch (release) testing
SAFETY/EFFICACY (Bioanalysis)
- Development and validation of bioanalytical methods
- PK/TK studies
- Immunogenicity studies
- Biomarker studies

The Quality Assistance environment is GMP, GLP and GCLP/GCP compliant.

Visit www.quality-assistance.com for more information

Our company is recognized for excellence in providing ISO 9001monoclonal and polyclonal antibodies, antigens, enzymes, and purified proteins to the research and medical diagnostic marketplace. Nearly all of our products are validated for usage in quantitative sandwich immunoassay and qualitative rapid testing.

We offer immunological reagents worldwide for diagnostics & research in the following disciplines:

Infectious Diseases (60)
Neuroscience (45)
Inflammation (43)
Veterinary (41)
Cardiac Markers (36)
Gangliosides & Globosides (33)
Tumor Markers (26)
Hormones (22)
Microbial & Plant Toxins (21)
Metabolic Syndrome (15)
Blood Coagulation and Anemia (12)
Biodefense (10)
Kidney Diseases (4)
Fertility and Pregnancy (2)


We are happy to inform you that Advanced ImmunoChemical is now offering a set of antibodies produced In vitro. In addition, some of our current antibodies are now available both as In vivo- and In vitro-produced products.

Monoclonal antibodies and mammalian antigens for detecting infectious diseases, cardiac biomarkers, and hormones.

Broad selection antibodies and inactivated viral antigens to detect Influenza A and B in clinical samples.
Monoclonal antibodies for the detection of biological threats and dangerous pathogens.

Biomarkers for cardiovascular disease prevention, risk assessment, and diagnostics.

Customers Include: Princeton University, Duke University School of Medicine, Columbia University Medical Center, CDC, National Institutes of Health, Naval Health Research Center, Los Alamos National Laboratory, US Army Medical Research Institute of Infectious Diseases, Sandia National Laboratories, Stanfored Medicine, NIST, NIMH, Harvard Medical School, Yale University School of Medicine, John Hopkins School of Medicine, Lawrence Livermore National Laboratory, and many more!

Advanced ImmunoChemical is a WBENC-certified woman-owned small business, since 1986.

Founded in 2013, BioAscent is a leading provider of integrated drug discovery services. Our expert scientists provide medicinal chemistry, in vitro biosciences and compound management services from our base in the former Organon / Merck Sharpe and Dohme (MSD) R&D site in Newhouse, Scotland, and via Compound Cloud we offer access to an IP-free compound library in assay ready format.

Our drug discovery services include de novo assay development, target analysis and bespoke screening strategies, compound screening, medicinal and synthetic chemistry, computational chemistry and data management (>100 biochemical and biophysical assays established for drug discovery projects, >50 hit validation/characterisation projects, and >25 hit-to-lead campaigns since 2013). Our team of expert scientists has experience of successfully working from assay development through to preclinical and clinical candidates across all biological target classes and major therapeutic indications.

We currently hold and manage over 1 million compounds for our customers in our €20 million facility, storing and managing customer libraries ranging in size from a few thousand to a few hundred thousand compounds in both liquid and solid formats. We constantly receive and aggregate new compounds from our customers and their chemistry CRO partners, and ship in the assay-ready format of choice to their screening laboratories

Via our Compound Cloud service, we provide rapid access to an IP-free library of ~125,000 lead like compounds in screening-ready format. Our expertise in cherry picking, reformatting, shipping and data management have allowed us to deliver over 80,000 screening plates globally to our customers and their partner testing laboratories since 2013.

We are located in modern purpose-built laboratories on a single site, the former Organon / Merck Sharpe and Dohme (MSD) research & development facility, based within the BioCity Scotland campus at Newhouse, Scotland, UK.

Within Basel neighbourhood and at the very heart of Europe (the triple border of France, Germany and Switzerland), Firalis is a pioneering biotechnology company, active in discovery, development and qualification of biomarkers (BM).

1) BIOMARKER PRODUCTS
Firalis develops BM-based diagnostic, prognostic and theranostic tools:
● RUO Kits (Research-Use-Only), based on validated innovative biomarkers
● IVD Tools (In Vitro Diagnostic), based on a combination of clinically qualified biomarkers

2) BIOMARKER R&D
● Development of proprietary BMs
- Cardiovascular, Inflammatory, Autoimmune and Neurology
● Drug Safety & Drug Efficacy
● Patient Stratification
● Personalized Medicine

3) BIOMARKER-RELATED CRO SERVICES
BM Discovery for laboratories, biotechs and pharmaceutical industry:
- Proteomics: Soluble biomarker measurements with several immunoassays technologies (ELISA, multiplex and high sensitivity platforms such as Luminex® BioPlex 200™, Meso Scale Discovery®, Singulex Erenna®, Protein Simple Ella™, Olink and Siemens Dimension® EXL™ 200)
- Genomics/Transcriptomics: Targeted sequencing of miRNA and mRNA (HTG EdgeSeq), lncRNA screening via Firalis proprietary platform, Next-Generation Sequencing (NGS) services (RNA-Seq, whole genome and exome sequencing, etc.) and qPCR/microfluidic qPCR (Gene Expression, SNP, CNV, etc.)
- Flow Cytometry: Immunophenotyping of preclinical and clinical samples, monitoring of pharmacodynamics on target cells in response to treatment and biomarker discovery
- Assay development and validation on various platforms, development of critical reagents (antibodies and proteins)
- Biobanking and sample repository services supported by LIMS
- Data analysis using multi-parametric statistics and development of predictive models
- Support of regulatory activities related to biomarker qualification with Health Authorities (FDA/EMA)
- Quality environment (ISO 9001, ISO 13485 (GMP), ISO 17025 (GLP/GCLP))

For more information please visit our website.

HalioDx is an immuno-oncology diagnostic company providing oncologists and drug development organizations with first-in-class Immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies.

Leveraging the pioneering work of Dr Jérôme Galon, HalioDx provides a unique range of immune scoring solutions including its flagship Immunoscore® assay for the assessment of the immune contexture of a tumor, as a key determinant of patients’ outcomes and response to cancer treatments.

HalioDx has developed a unique Biopharma partnering ecosystem for the identification of clinically relevant biomarker signatures, the demonstration of their clinical utility in trials and the development and commercialization of resulting diagnostic or companion diagnostic tests. Our programs draw on our expertise and focus on immuno-oncology, a complete suite of genomic and proteomic biomarker profiling services, a world-class data analysis and biostatistics platform, and CLIA-certified laboratories with compliant facilities in Europe and in the US to develop, manufacture, register and market in vitro diagnostic (IVD) products. HalioDx has rapidly become the preferred partner of Biopharma developing therapeutic antibodies, vaccines, chemotherapies, oncolytic peptides, and CAR-T cell therapies.

About Immunoscore®
Immunoscore® is an in vitro diagnostic test measuring the host immune response at the tumor site. It provides a robust, precise, quantitative, and consensus assessment of lymphocytic infiltration and has been shown to predict patient outcome and response to therapies in several indications.
Immunoscore® was included in the 2020 European Society of Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up for Localized Colon Cancer.
Immunoscore® is commercially available in more than 20 countries.